These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 25894901

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB.
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
    Sime FB, Hahn U, Warner MS, Tiong IS, Roberts MS, Lipman J, Peake SL, Roberts JA.
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807922
    [Abstract] [Full Text] [Related]

  • 8. Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.
    Thabit AK, Grupper M, Nicolau DP, Kuti JL.
    J Pharm Pract; 2017 Dec; 30(6):593-599. PubMed ID: 29121839
    [Abstract] [Full Text] [Related]

  • 9. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
    Kim A, Sutherland CA, Kuti JL, Nicolau DP.
    Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.
    Felton TW, Hope WW, Lomaestro BM, Butterfield JM, Kwa AL, Drusano GL, Lodise TP.
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4087-94. PubMed ID: 22585219
    [Abstract] [Full Text] [Related]

  • 13. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.
    Cheatham SC, Fleming MR, Healy DP, Chung CE, Shea KM, Humphrey ML, Kays MB.
    Int J Antimicrob Agents; 2013 Jan; 41(1):52-6. PubMed ID: 23228881
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, Soraluce A, Maynar J, Sánchez-Izquierdo JÁ, Isla A.
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ, Shankar V, Schlichting C, Kuti JL.
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia.
    Cies JJ, Jain J, Kuti JL.
    Pediatr Blood Cancer; 2015 Mar; 62(3):477-82. PubMed ID: 25328131
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.